Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial

International Journal of Radiation Oncology Biology Physics

Volumn 53, Issue 5, 2002, Pages 1097-1105

  Pollack, Alan ^a,b   Zagars, Gunar K ^a   Starkschall, George ^a   Antolak, John A ^a   Lee, J Jack ^a   Huang, Eugene ^a   Von Eschenbach, Andrew C ^a   Kuban, Deborah A ^a   Rosen, Isaac ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

Dose; Prostate specific antigen; Radiotherapy; Rectal toxicity

Indexed keywords

PATIENT MONITORING; RADIATION; REGRESSION ANALYSIS; TOXICITY; TUMORS;

ESCALATION;

RADIOTHERAPY;

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BIOCHEMISTRY; BLADDER DISEASE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FOLLOW UP; GASTROINTESTINAL TOXICITY; HAZARD ASSESSMENT; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION DOSE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; RECTUM DISEASE; REGRESSION ANALYSIS; TREATMENT OUTCOME;

AGED; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036680314     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)02829-8     Document Type: Article

References (36)

1. Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone
2. External beam radiotherapy for stage T1/T2 prostate cancer: How does it stack up?
3. Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions
4. External beam radiotherapy dose-response characteristics of 1127 men with prostate cancer treated in the PSA era
5. Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate
6. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer
7. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer
8. Late effects after radiotherapy for prostate cancer in a randomized dose-response study: Results of a self-assessment questionnaire
9. Complications from dose escalation in prostate cancer: Preliminary results of a randomized trial
10. Sample size requirements and length of study for testing interaction in a 2 × k factorial design when time-to-failure is the outcome
11. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)
12. Late effects toxicity scoring: The SOMA scale
13. Chronic rectal bleeding after high-dose conformal treatment of prostate cancer warrants modification of existing morbidity scales
14. Consensus statement: Guidelines for PSA following radiation therapy
15. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: Further evidence for a significant dose effect
16. Conformal irradiation of the prostate: Estimating long-term rectal bleeding risk using dose-volume histograms
17. Patterns of care studies: Dose-response observations for local control of adenocarcinoma of the prostate
18. The effect of dose on local control of prostate cancer
19. Irradiation of carcinoma of the prostate localized to the pelvis: Analysis of tumor response and prognosis
20. Definitive radiation therapy in carcinoma of the prostate localized to the pelvis: Experience at the Mallinckrodt Institute of Radiology
21. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406
22. Dose escalation with 3D-CRT in prostate cancer: French study of dose escalation with conformal 3D radiotherapy in prostate cancer - Preliminary results
23. Cancer surveillance series: Interpreting trends in prostate cancer incidence, mortality and survival rates
24. Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice
25. Declining rates of extracapsular extension after radical prostatectomy: Evidence for continued stage migration
26. External beam radiotherapy dose response of prostate cancer
27. Radiation dose response in patients with favorable localized prostate cancer (stage T1-T2, biopsy Gleason < or = 6, and pretreatment prostate-specific antigen < or = 10)
28. Defining the appropriate radiation dose for pretreatment PSA < or = 10 ng/mL prostate cancer
29. Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer
30. Does pelvic irradiation play a role in the management of prostate cancer?
31. A phase III trial comparing whole pelvis (WP) to prostate only (PO) radiotherapy, and neoadjuvant to adjuvant total androgen suppression (TAS): Preliminary analysis of RTOG 9413
32. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: A randomised trial
33. Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer
34. Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy